Photobiomodulation for Blood Pressure and Heart Rate Reduction in Mastectomized Women on Hormone Blockers: A Randomized Controlled Trial

被引:1
作者
Pacheco, Juliano Abreu [1 ,2 ]
Molena, Kelly Fernanda [3 ]
Veiga, Eugenia Velludo [4 ]
机构
[1] Univ Sao Paulo, Ribeirao Preto Coll Nursing, Dept Gen & Specialized Nursing, Postgrad Program, Ribeirao Preto, Brazil
[2] Sobeccan Hosp Fdn, Ribeirao Preto Canc Hosp, Ribeirao Preto, Brazil
[3] Univ Sao Paulo, Sch Dent Ribeirao Preto, Dept Pediat Dent, Ribeirao Preto, Brazil
[4] Univ Sao Paulo, Ribeirao Preto Coll Nursing, Dept Gen & Specialized Nursing, Ribeirao Preto, Brazil
关键词
blood pressure; heart rate; breast neoplasms; low-level laser therapy; tamoxifen; aromatase inhibitors; POSTMENOPAUSAL WOMEN; SMOOTH-MUSCLE; LASER THERAPY; TAMOXIFEN; PROLIFERATION; CANCER;
D O I
10.1089/photob.2023.0136
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective: To assess the impact of intravascular laser irradiation of blood (ILIB) on the primitive carotid artery (PCA) hemodynamic variables, specifically blood pressure (BP) and heart rate (HR), in mastectomized patients undergoing hormone blocker treatments. Materials and methods: This study is a controlled, experimental, and randomized clinical trial. Patients were allocated into two groups: the experimental group (G1)-patients who received ILIB therapy using a 660 nm laser targeted at the PCA, and the control group (G2)-patients who did not receive ILIB therapy. Clinical research was conducted weekly, with measurements of systolic blood pressure (SBP), diastolic blood pressure (DBP), and HR. The Mann-Whitney U test for independent samples was used, with a significance level of alpha = 0.05. Results: Systemic photobiomodulation on the PCA did not demonstrate a statistically significant difference in relation to SBP and DBP. However, for HR, the p-value was <0.05, indicating a significant difference between G1 and G2. The initial mean p > decreased from 142.3 to 116.4 mmHg in G1, and from 130.4 to 119.8 mmHg in G2. The DBP varied from 78.8 to 72.8 mmHg in G1, and from 79.1 to 74.2 mmHg in G2. A statistically significant difference was observed in HR, decreasing from 81.3 to 62.06 bpm in G1, and changing minimally from 74.1 to 75.1 bpm in G2. A considerable reduction was present in the timing of application. Conclusions: ILIB therapy applied to the PCA induces a reduction in BP and, more notably, HR in mastectomized women using the tamoxifen or aromatase inhibitors.
引用
收藏
页码:294 / 305
页数:12
相关论文
共 53 条
[1]  
Abreu FMC., 2021, ED
[2]  
Pacheco JA, 2019, American Journal of Biomedical Science & Research, V4, P271, DOI [10.34297/ajbsr.2019.04.000813, 10.34297/AJBSR.2019.04.000813, DOI 10.34297/AJBSR.2019.04.000813]
[3]   Cardiotoxicity associated with cancer therapy: Pathophysiology and prevention strategies [J].
Adao, Rui ;
de Keulenaer, Gilles ;
Leite-Moreira, Adelino ;
Bras-Silva, Carmen .
REVISTA PORTUGUESA DE CARDIOLOGIA, 2013, 32 (05) :395-409
[4]  
Botelho LOD, 2022, Revista Brasileira de Cancerologia, V68, DOI [10.32635/2176-9745.rbc.2022v68n2.1960, 10.32635/2176-9745.RBC.2022v68n2.1960, DOI 10.32635/2176-9745.RBC.2022V68N2.1960]
[5]   Hormone therapy and venous thromboembolism among postmenopausal women -: Impact of the route of estrogen administration and progestogens:: The ESTHER study [J].
Canonico, Marianne ;
Oger, Emmanuel ;
Plu-Bureau, Genevieve ;
Conard, Jacqueline ;
Meyer, Guy ;
Levesque, Herve ;
Trillot, Nathalie ;
Barrellier, Marie-Therese ;
Wahl, Denis ;
Emmerich, Joseph ;
Scarabin, Pierre-Yves .
CIRCULATION, 2007, 115 (07) :840-845
[6]   Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [J].
Chobanian, AV ;
Bakris, GL ;
Black, HR ;
Cushman, WC ;
Green, LA ;
Izzo, JL ;
Jones, DW ;
Materson, BJ ;
Oparil, S ;
Wright, JT ;
Roccella, EJ .
HYPERTENSION, 2003, 42 (06) :1206-1252
[7]   IMPLICATIONS OF SMALL REDUCTIONS IN DIASTOLIC BLOOD-PRESSURE FOR PRIMARY PREVENTION [J].
COOK, NR ;
COHEN, J ;
HEBERT, PR ;
TAYLOR, JO ;
HENNEKENS, CH .
ARCHIVES OF INTERNAL MEDICINE, 1995, 155 (07) :701-709
[8]  
da Silva RWT., 2022, AUTHOREA, DOI [10.22541/au.166038454.40157124/v1, DOI 10.22541/AU.166038454.40157124/V1]
[9]  
de Carvalho DLC, 2019, BIOL BLOOD MARROW TR, V25, pS305, DOI [10.1016/j.bbmt.2018.12.659, 10.1016/j.bbmt.2018.12.659, DOI 10.1016/J.BBMT.2018.12.659]
[10]  
Pereira RDD, 2018, REV LAT-AM ENFERM, V26